# TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant

> **NCT03737604** · PHASE4 · RECRUITING · sponsor: **University of California, Davis** · enrollment: 200 (estimated)

## Conditions studied

- Transplant;Failure,Kidney
- Pain, Postoperative

## Interventions

- **DRUG:** Ropivacaine Continuous Infusion Catheter
- **DRUG:** Single Dose Liposomal Bupivicaine

## Key facts

- **NCT ID:** NCT03737604
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-10-04
- **Primary completion:** 2026-06-12
- **Final completion:** 2026-06-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03737604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03737604, "TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03737604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*